文献速递心律失常心力衰竭与心肌病

NT-proBNP与非抗凝房颤患者临床特征及心血管结局的关系

NT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillation.
PubMed 文献 · Heart · 2026-08-17

本研究基于两项多中心临床试验中3183例未抗凝房颤患者,基线检测NT-proBNP并随访中位18个月。基线心电图房颤是NT-proBNP最强的相关临床因素,房颤时浓度是窦性心律的4.2倍。NT-proBNP独立关联缺血性卒中、心衰住院、心血管死亡和全因死亡,且基线心律不影响这些关联。

要点

  • 未抗凝房颤患者中,NT-proBNP独立关联缺血性卒中、心衰住院及死亡风险。
  • 基线房颤心律使NT-proBNP浓度较窦性心律高4.2倍,为最强相关因素。
  • 无论基线心律如何,NT-proBNP与结局的关联保持一致。

核心结论

  • 在未抗凝的房颤患者中,NT-proBNP水平与临床结局风险显著相关。
  • 基线房颤心律是与NT-proBNP水平最强的相关临床因素。
  • NT-proBNP与结局的关联不受基线心律影响。

研究设计与样本

  • 基于两项多中心临床试验,纳入3183例随机接受阿司匹林的房颤患者,中位随访18个月。
  • 基线血浆样本采用Elecsys免疫分析法检测NT-proBNP。
  • 采用多变量线性回归分析NT-proBNP与临床特征关联,Cox回归评估临床结局,C统计量评价预后价值。

主要发现

  • 基线心电图房颤患者NT-proBNP浓度为窦性心律者的4.2倍。
  • NT-proBNP第三四分位组较第一四分位组缺血性卒中HR 2.07(95%CI 1.46-2.94)。
  • NT-proBNP第三四分位组较第一四分位组心衰住院HR 2.16(95%CI 1.59-2.92)。
  • NT-proBNP第三四分位组较第一四分位组心血管死亡HR 2.43(95%CI 1.79-3.30)。
  • NT-proBNP第三四分位组较第一四分位组全因死亡HR 2.09(95%CI 1.65-2.65)。

临床怎么用

  • 在未抗凝房颤患者中可检测NT-proBNP以辅助风险评估。
  • NT-proBNP升高提示缺血性卒中、心衰住院及死亡风险增加,需加强监测。
  • 解读NT-proBNP预后价值时无需因基线心律不同而调整。

局限性

  • 研究人群为随机接受阿司匹林的未抗凝房颤患者,结果外推需谨慎。
  • NT-proBNP仅在基线检测,未评估动态变化。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: N-terminal pro-B-type natriuretic peptide (NT-proBNP) is a well-established biomarker for cardiovascular risk; however, its prognostic value in patients with atrial fibrillation (AF) who are not receiving anticoagulation therapy has not been well established. We investigated the association between NT-proBNP levels, clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with AF and assessed whether baseline heart rhythm modified these associations. METHODS: Plasma samples were obtained at baseline in two multicentre clinical trials involving 3183 patients with AF randomised to aspirin with a median follow-up of 18 months. NT-proBNP was analysed using the Elecsys immunoassay. Associations between NT-proBNP and clinical characteristics were assessed by multivariable linear regression. Associations with clinical outcomes were evaluated using Cox regression models. The prognostic value of NT-proBNP was evaluated with C-statistics. RESULTS: AF on the baseline ECG was the clinical factor most strongly associated with NT-proBNP levels, with concentrations 4.2 times higher in AF than in sinus rhythm. NT-proBNP was independently associated with ischaemic stroke (the third sample quartile compared with the first, HR 2.07, 95% CI 1.46 to 2.94), heart failure hospitalisation (HR 2.16, 95% CI 1.59 to 2.92), cardiovascular death (HR 2.43, 95% CI 1.79 to 3.30) and all-cause death (HR 2.09, 95% CI 1.65 to 2.65) during follow-up. There was no interaction between heart rhythm and the associations between NT-proBNP and outcomes (all p values ≥0.07). CONCLUSIONS: In non-anticoagulated patients with a diagnosis of AF, NT-proBNP levels were significantly associated with the risk of clinical outcomes. Baseline AF rhythm was the clinical factor most strongly associated with NT-proBNP levels. However, the associations between NT-proBNP and outcomes remained consistent regardless of baseline rhythm.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Tomasdottir, Oldgren, Lindbäck, et al. NT-proBNP in relation to clinical characteristics and cardiovascular outcomes in non-anticoagulated patients with atrial fibrillation. Heart. 2026. PMID: 42608180. doi:10.1136/heartjnl-2026-328033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。